40 min listen
The CRO scientist turned entrepreneur
The CRO scientist turned entrepreneur
ratings:
Length:
44 minutes
Released:
May 26, 2023
Format:
Podcast episode
Description
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Richard Weaver, Founder and Managing Director at Drug Discovery Solutions.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:
How his curiosity to learn at AZ led him to realizing he was an entrepreneur
The opportunistic start-up story and impressive growth journey of XenoGesis up to the eventual, successful sale to Sygnature Discovery in 2020
Lessons learned and milestone moments of a scientific entrepreneur
Why biotechs are here to stay... outsourcing is here to stay... but why offshoring is not
Richard is Founder and Managing Director of Drug Discovery Solutions Limited. Previously CEO and founder of XenoGesis, he grew and led the successful sale of the business to Sygnature Discovery in 2020. Prior to that, he spent 14 years at AstraZeneca.
He is an expert of all aspects of R&D including Due Diligence of companies/assets. Specialist in Drug Metabolism & Pharmacokinetics (DMPK) from Hit Identification (HI) to Candidate Drug (CD) nomination and pre-clinical development.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:
How his curiosity to learn at AZ led him to realizing he was an entrepreneur
The opportunistic start-up story and impressive growth journey of XenoGesis up to the eventual, successful sale to Sygnature Discovery in 2020
Lessons learned and milestone moments of a scientific entrepreneur
Why biotechs are here to stay... outsourcing is here to stay... but why offshoring is not
Richard is Founder and Managing Director of Drug Discovery Solutions Limited. Previously CEO and founder of XenoGesis, he grew and led the successful sale of the business to Sygnature Discovery in 2020. Prior to that, he spent 14 years at AstraZeneca.
He is an expert of all aspects of R&D including Due Diligence of companies/assets. Specialist in Drug Metabolism & Pharmacokinetics (DMPK) from Hit Identification (HI) to Candidate Drug (CD) nomination and pre-clinical development.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
Released:
May 26, 2023
Format:
Podcast episode
Titles in the series (100)
Leading a top tier CDMO: In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with JoyL Silva, General Manager at Pfizer CentreOne. JoyL joined Pfizer over 20 years ago and has successfully risen through a series of ... by Molecule to Market: Inside the outsourcing space